BeOne Medicines AG (SHA:688235)
298.21
-3.64 (-1.21%)
Sep 29, 2025, 11:30 AM CST
BeOne Medicines AG Revenue
BeOne Medicines AG had revenue of $1.32B USD in the quarter ending June 30, 2025, with 41.56% growth. This brings the company's revenue in the last twelve months to $4.56B, up 47.33% year-over-year. In the year 2024, BeOne Medicines AG had annual revenue of $3.81B with 54.96% growth.
Revenue (ttm)
$4.56B
Revenue Growth
+47.33%
P/S Ratio
7.84
Revenue / Employee
$414.73K
Employees
11,000
Market Cap
256.06B CNY
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Jiangsu Hengrui Medicine | 30.15B |
WuXi AppTec | 41.90B |
Shenzhen Mindray Bio-Medical Electronics | 32.94B |
Sichuan Biokin Pharmaceutical | 441.19M |
Zhangzhou Pientzehuang Pharmaceutical., | 10.52B |
Shanghai United Imaging Healthcare | 10.98B |
Aier Eye Hospital Group | 21.94B |
Yunnan Baiyao Group Co.,Ltd | 40.84B |
BeOne Medicines AG News
- 4 weeks ago - BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up - Benzinga
- 7 weeks ago - A Glimpse of BeiGene's Earnings Potential - Benzinga
- 7 weeks ago - BeiGene's Earnings: A Preview - Benzinga
- 7 weeks ago - BeiGene Q2 2025 Earnings Preview - Seeking Alpha
- 3 months ago - Glenmark Pharmaceuticals launches TEVIMBRA in India for advanced lung and esophageal cancer treatment - Business Upturn
- 3 months ago - Glenmark Pharmaceuticals to launch Zanubrutinib (BRUKINSA) in India after DCGI approval - Business Upturn
- 4 months ago - Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple - Investor's Business Daily
- 4 months ago - BeiGene gets EU backing for neck and head cancer treatment - Seeking Alpha